Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Di | WHO recommends second malaria vaccine for children | ||
Di | Sanofi enters agreement with Janssen to develop E. coli vaccine candidate | ||
Di | NFID and CDC urge US adults to get vaccinated against flu and COVID-19 | ||
Di | Man vs microbe: the fight against antimicrobial resistance | ||
Di | Dollo's law | ||
Mo | Nobel Prize in Medicine awarded to pair of scientists behind mRNA COVID-19 vaccines | ||
Mo | Biogen's Actemra biosimilar approved by FDA to treat adult and paediatric arthritis | ||
Mo | Regeneron's odronextamab granted FDA priority review for non-Hodgkin lymphoma | ||
Mo | The impact of prostate cancer on global health | ||
Mo | Improvement in rare disease diagnosis and care | ||
Fr | Further data for AstraZeneca/Daichii Sankyo's Enhertu for breast cancer requested by NICE | ||
Fr | Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate | ||
Fr | EDX Medical Group develops multi-disease rapid tests | ||
Fr | ScreenPoint Medical to showcase AI software at European scientific meeting | ||
Do | NIHR launches new framework to highlight health progress outcomes | ||
Do | Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases | ||
Do | UKHSA secures UK-based vaccine deal for future influenza pandemics | ||
27.09. | Novo Nordisk and Valo Health collaborate in deal worth up to $3.3bn | ||
27.09. | A landscape review reveals £1.1bn of UK funding for rare diseases | ||
27.09. | Cancer Research UK partners with French cancer institute | ||
27.09. | Diagnosis pathway launched to mark European Myeloma Day | ||
26.09. | Sandoz biosimilar receives EC approval to treat MS | ||
26.09. | Pfizer's Abrysvo RSV vaccine for infants backed by US CDC | ||
26.09. | CDC provides $262.5m to create national network for infectious diseases | ||
25.09. | Novo Nordisk Foundation commits €127m for new cell therapy facility |